Karen R Watkins1, Jane E Rogers, Bradley Atkinson. 1. University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 377, Houston, TX, 77030, USA, karen.eckmann@gmail.com.
Abstract
PURPOSE: Denosumab is approved for the prevention of skeletal-related events (SREs) in metastatic solid tumor patients with bone metastases. Limited data regarding the safety of denosumab in patients with severe renal insufficiency suggests increased rates of hypocalcemia compared to patients with normal renal function. The purpose of this study was to assess the rates of hypocalcemia and hypophosphatemia in cancer patients with severe renal impairment. METHODS: In this case series, patient demographics, primary tumor site, number of denosumab doses, and episodes of hypocalcemia and hypophosphatemia were retrospectively obtained by patient chart review. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault equation. Twenty-two metastatic solid tumor patients with severe renal insufficiency (creatinine clearance <30 mL/min) who had received denosumab at a dose of 120 mg were included. RESULTS: Ten of 22 patients (45 %) experienced a hypocalcemic event of any grade. Three patients (14 %) had grade 3 hypocalcemia, and no patients had grade 4 hypocalcemia. The median number of doses of denosumab prior to calcium nadir was one. Seven of 22 patients (32 %) experienced hypophosphatemia of any grade including grade 3 events in two patients (9 %). CONCLUSIONS: Denosumab resulted in increased rates of hypocalcemia when administered to metastatic solid tumor patients with severe renal impairment for the prevention of SREs compared to previously reported rates of hypocalcemia in the general population. However, all cases of hypocalcemia were asymptomatic and resolved prior to subsequent dosing. Due to a higher rate of hypocalcemia than reported in patients with normal renal function, patients with severe renal impairment should receive close monitoring of calcium levels while receiving denosumab.
PURPOSE:Denosumab is approved for the prevention of skeletal-related events (SREs) in metastatic solid tumorpatients with bone metastases. Limited data regarding the safety of denosumab in patients with severe renal insufficiency suggests increased rates of hypocalcemia compared to patients with normal renal function. The purpose of this study was to assess the rates of hypocalcemia and hypophosphatemia in cancerpatients with severe renal impairment. METHODS: In this case series, patient demographics, primary tumor site, number of denosumab doses, and episodes of hypocalcemia and hypophosphatemia were retrospectively obtained by patient chart review. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault equation. Twenty-two metastatic solid tumorpatients with severe renal insufficiency (creatinine clearance <30 mL/min) who had received denosumab at a dose of 120 mg were included. RESULTS: Ten of 22 patients (45 %) experienced a hypocalcemic event of any grade. Three patients (14 %) had grade 3 hypocalcemia, and no patients had grade 4 hypocalcemia. The median number of doses of denosumab prior to calcium nadir was one. Seven of 22 patients (32 %) experienced hypophosphatemia of any grade including grade 3 events in two patients (9 %). CONCLUSIONS:Denosumab resulted in increased rates of hypocalcemia when administered to metastatic solid tumorpatients with severe renal impairment for the prevention of SREs compared to previously reported rates of hypocalcemia in the general population. However, all cases of hypocalcemia were asymptomatic and resolved prior to subsequent dosing. Due to a higher rate of hypocalcemia than reported in patients with normal renal function, patients with severe renal impairment should receive close monitoring of calcium levels while receiving denosumab.
Authors: Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544
Authors: Breanne Lechner; Carlo DeAngelis; Noreen Jamal; Urban Emmenegger; Natalie Pulenzas; Angie Giotis; Parker Sheehan; May Tsao; Gillian Bedard; Edward Chow Journal: Support Care Cancer Date: 2014-02-11 Impact factor: 3.603
Authors: M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann Journal: Ann Oncol Date: 2007-09-28 Impact factor: 32.976